Kalytera Therapeutics Inc is a clinical-stage pharmaceutical company developing next-generation cannabinoid therapeutics. Kalytera develops novel cannabinoid medicines for a range of medical needs with an initial focus on graft-versus-host disease (GvHD). Kalytera also develops a new class of proprietary cannabidiol (CBD) therapeutics. Kalytera acquired its GvHD program from Israel-based Talent Biotechs in early 2017 based on the results of Talents' four phase-2a clinical studies in the prevention and treatment of GvHD using CBD.